Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023GlobeNewsWire • 10/24/23
Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung CancerGlobeNewsWire • 10/23/23
Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual MeetingGlobeNewsWire • 10/03/23
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial UseGlobeNewsWire • 09/21/23
Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer Accepted for Oral Presentation at ESMO Congress 2023GlobeNewsWire • 07/31/23
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue SarcomaGlobeNewsWire • 07/28/23
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway InhibitorGlobeNewsWire • 06/27/23
Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3GlobeNewsWire • 06/20/23
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual MeetingGlobeNewsWire • 06/05/23
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement OfferGlobeNewsWire • 06/02/23